Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0CAEXH
ADC Name
RC-118
Synonyms
RC-118; RC118; RC118-ADC,YH005; Recombinant humanized IgG1 anti-Claudin18.2 monoclonal antibody conjugated to MMAE; YH-005; YH005; YH005-ADC
   Click to Show/Hide
Organization
RemeGen Co., Ltd.; Biocytogen Pharmaceuticals (Beijing) Co., Ltd.; Eucure (Beijing) Biopharma Co., Ltd.
Drug Status
Phase 1/2
Indication
In total 1 Indication(s)
Solid tumor
Phase 2
Clinical Trial
Drug-to-Antibody Ratio
3.5-4.5
Structure
Antibody Name
Ciletatug
  Antibody Info 
Antigen Name
Claudin-18.2 (CLDN18.2)
  Antigen Info 
Payload Name
Monomethyl auristatin E
  Payload Info 
Therapeutic Target
Microtubule (MT)
  Target Info 
Linker Name
Mc-Val-Cit-PABC
  Linker Info 
Conjugate Type
Undisclosed
Combination Type
vedotin
Special Approval(s)
Orphan drug(FDA)
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 3 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Undisclosed  NCT05205850
Phase 1
An open, multi-center phase 1/2a clinical study of RC118 for injection in patients with locally advanced unresectable or metastatic malignant solid tumors with positive expression of CLAUDIN 18.2.
Undisclosed  NCT04914117
Phase 1
Phase 1, first-in-human, multicentre, open-label study of RC118 for injection in patients with locally advanced unresectable/metastatic solid tumours.
Undisclosed  NCT03895112
Phase 1
Phase 1 study of AVID200 in patients with myelofibrosis (myeloproliferative neoplasms research consortium [MPN-RC] 118).
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 3 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Related Clinical Trial
NCT Number NCT05205850  Clinical Status Phase 1
Clinical Description An open, multi-center phase 1/2a clinical study of RC118 for injection in patients with locally advanced unresectable or metastatic malignant solid tumors with positive expression of CLAUDIN 18.2.
Experiment 2 Reporting the Activity Date of This ADC [2]
Related Clinical Trial
NCT Number NCT04914117  Clinical Status Phase 1
Clinical Description Phase 1, first-in-human, multicentre, open-label study of RC118 for injection in patients with locally advanced unresectable/metastatic solid tumours.
Experiment 3 Reporting the Activity Date of This ADC [3]
Related Clinical Trial
NCT Number NCT03895112  Clinical Status Phase 1
Clinical Description Phase 1 study of AVID200 in patients with myelofibrosis (myeloproliferative neoplasms research consortium [MPN-RC] 118).
References
Ref 1 An Open, Multi-center Phase I/IIa Clinical Study of RC118 for Injection in Patients With Locally Advanced Unresectable or Metastatic Malignant Solid Tumors With Positive Expression of Claudin 18.2, NCT05205850
Ref 2 Phase 1, First-in-Human, Multicentre, Open-label Study of RC118 for Injection in Patients With Locally Advanced Unresectable/Metastatic Solid Tumours, NCT04914117
Ref 3 Phase I Study of AVID200 in Patients With Myelofibrosis (Myeloproliferative Neoplasms Research Consortium [MPN-RC] 118), NCT03895112